Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Janisch

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 13, 2005
A phase I study of antisense oligonucleotide GTI-2040 given by continuous intravenous infusion in patients with advanced solid tumorsA A Desai, R L Schilsky, A Young, et al.
The Pharmacogenomics Journal|May 7, 2002
UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicityL Iyer, S Das, L Janisch, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1993
Phase I clinical and pharmacology study of 502U83 given as a 24-h continuous intravenous infusionR L Schilsky, M J Ratain, L Janisch, et al.
Muscle & Nerve|January 1, 1997
Evaluation of neuropathy in patients on suramin treatmentB Soliven, U K Dhand, K Kobayashi, et al.
European Journal of Cancer (Oxford, England : 1990)|March 29, 2011
A phase I study of sirolimus and bevacizumab in patients with advanced malignanciesE E W Cohen, M R Sharma, L Janisch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 3, 2004
A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabineS D Undevia, H L Kindler, L Janisch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 29, 1998
Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancerR L Schilsky, J Hohneker, M J Ratain, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 13, 2005
A phase I study of antisense oligonucleotide GTI-2040 given by continuous intravenous infusion in patients with advanced solid tumorsA A Desai, R L Schilsky, A Young, et al.
The Pharmacogenomics Journal|May 7, 2002
UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicityL Iyer, S Das, L Janisch, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1993
Phase I clinical and pharmacology study of 502U83 given as a 24-h continuous intravenous infusionR L Schilsky, M J Ratain, L Janisch, et al.
Muscle & Nerve|January 1, 1997
Evaluation of neuropathy in patients on suramin treatmentB Soliven, U K Dhand, K Kobayashi, et al.
European Journal of Cancer (Oxford, England : 1990)|March 29, 2011
A phase I study of sirolimus and bevacizumab in patients with advanced malignanciesE E W Cohen, M R Sharma, L Janisch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 3, 2004
A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabineS D Undevia, H L Kindler, L Janisch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 29, 1998
Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancerR L Schilsky, J Hohneker, M J Ratain, et al.
Pageof 3